Peter Orszag, the Director of the Office of Management and Budget, believes that health costs are the #1 driver of America’s long-term deficit. The inexorable increase of health costs are plaguing the Federal budget, Governors’ state budgets, employers’ bottom-lines and ability to compete globally, and household budgets.
Things are looking up for next year when it comes to health costs in 2010 – they’ll continue to grow at double-digit rates, according to Buck Consultants, the employer benefits consultancy.
Buck’s 2009 National Health Care Trend Survey finds that costs for all flavors of health plans – including PPOs, POS, HMO and consumer-driven/high-deductible – will increase between 10.2% and 11.0% into 2010.
The rate of increase has declined very slightly across-the-plans, from 0.1% to 0.3%.
The growth in the cost of prescription drug trends among health plans is projected to decline 0.6%, but still increasing at a 10.8% trend.
Buck surveyed over 100 insurers, HMOs and TPAs covering about 95 million enrollees.
Health Populi’s Hot Points: The rise of health costs, especially in the current recession, is the front-burner issue in health reform. While universal coverage continues to be a priority for most Americans, that issue is sharply split across party lines. Getting health cost increases under control is something most Americans and policymakers can agree on in 2009.
Expect this issue to be front-and-center in health reform discussions this year, as double-digit cost increases are in reformers’ collective crystal ball.





Thank you
Jane joined host Dr. Geeta "Dr. G" Nayyar and colleagues to brainstorm the value of vaccines for public and individual health in this challenging environment for health literacy, health politics, and health citizen grievance.
I'm grateful to be part of the Duke Corporate Education faculty, sharing perspectives on the future of health care with health and life science companies. Once again, I'll be brainstorming the future of health care with a cohort of executives working in a global pharmaceutical company.